Clinical trial
Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic…
NCT00423670 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00423670 |
|---|---|
| Title | Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) |
| Official title | A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | boceprevir (SCH 503034), peginterferon-alfa 2b (PegIntron), ribavirin, ribavirin (low-dose) |
| Enrollment | 765 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Apr 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: